Tooth whitener safety
This article was originally published in The Tan Sheet
Executive Summary
Canadian researchers determine tooth-whitening products with hydrogen peroxide or carbamide peroxide do not increase users' risks for oral cancers, including people who abuse alcohol and/or are heavy smokers. The review of study literature, including unpublished studies with tests involving more than 4,000 people, was conducted by Ian Munro, PhD, associate director of the University of Toronto's Program in Food, Safety & Regulatory Affairs, et al., and published in the Journal of Esthetic & Restorative Dentistry, according to a Nov. 16 release. Exposures to hydrogen peroxide, which generally is the effective ingredient in tooth whiteners, are too low and, at 30 to 60 minutes, too brief to increase risks for oral cancer, the study results show. Concentrations of the substance quickly diminish to be nearly undetectable within 15 to 60 minutes. In March 2005, a European Union's Scientific Committee on Consumer Products 1opinion raised concerns about the safety of products containing the ingredients. In Europe, tooth whitening products with hydrogen peroxide or carbamide peroxide are only available to consumers from a dental practitioner, Munro et al. note...
You may also be interested in...
Shine More Safety Data On Tooth Whiteners With Hydrogen Peroxide – SCCP
The use of oral hygiene products and tooth whitening products containing more than 0.1 percent hydrogen peroxide cannot be deemed safe in the absence of long-term clinical data assessing possible adverse effects within the oral cavity, the European Commission's science panel says
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.